Clinical Trials Logo

Myotonic Disorders clinical trials

View clinical trials related to Myotonic Disorders.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05027269 Completed - Clinical trials for Myotonic Dystrophy 1

Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients

MARINA
Start date: October 28, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

AOC 1001-CS1 is a randomized, double-blind, placebo-controlled, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple-doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) patients (MARINA). Part A is a single dose design with 1 cohort (dose level). In Part A, the patient duration is 6 months as the treatment period is 1 day followed by a 6 month follow-up period. Part B is a multiple-ascending dose design with 2 cohorts (dose levels). In Part B, the patient duration is 6 months as the treatment period is 3 months followed by a 3 month follow-up period.

NCT ID: NCT02336477 Completed - Myotonia Congenita Clinical Trials

Mexiletine and Non Dystrophic Myotonias

MYOMEX
Start date: June 2011
Phase: Phase 3
Study type: Interventional

Treatment strategies in non-dystrophic myotonias are based on selective case reports, clinical experience and theoretical benefit. Presently, the most promising antimyotonic medication is mexiletine (MEX) but its manufacturing was stopped. The proposed randomized, double-blind, placebo-controlled, crossover trial is designed to: 1. study the safety and efficacy of mexiletine for the treatment of non-dystrophic myotonias 2. validate electromyographic tests as a standardized outcome measure of myotonia 3. assess the reliability and validity of a new clinical rating scale for myotonia

NCT ID: NCT02251457 Completed - Clinical trials for Myotonic Dystrophy 1

Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1

Start date: August 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to gather preliminary data to determine if ranolazine is a safe and effective treatment for the symptoms of myotonia congenital, paramyotonia congenita, and myotonic dystrophy type 1. The duration of the study is 5 weeks.

NCT ID: NCT01939561 Completed - Myotonia Congenita Clinical Trials

Lamotrigine as Treatment of Myotonia

Start date: November 2013
Phase: Phase 3
Study type: Interventional

Myotonia is a functional limiting symptom where the muscle stiffens on action leading to arrest of movement. Pharmacological treatment may make the difference between a physically restricted and a normal life. Today, patients with myotonia are treated with Mexiletine a medications resulting in adverse events up to 40 % and which very expensive and difficult to obtain. Our clinic has, forced by the above problems related to Mexiletine, treated a few patients with the drug Lamotrigine with pronounced positive effect in all. Lamotrigine belongs to the same category of drugs as Mexiletine but has fewer and milder side effects. Based on the similarities of the 2 drugs in pharmacological action and the positive experiences investigators are convinced that Lamotrigine will show a positive effect if evaluated in a broader scale. Due to the advantages of Lamotrigine compared to Mexiletine investigators find it of outmost importance for patients that this drug is assessed formally to establish Lamotrigine as a treatment choice for myotonia. Investigators believe that this will potentially make a huge difference in life quality for persons with myotonia. Investigators aim at investigating the efficacy and tolerability of Lamotrigine in the treatment of myotonia in a randomized doublet blinded placebo controlled crossover study.

NCT ID: NCT00244413 Completed - Myotonic Disorders Clinical Trials

Characteristics of Nondystrophic Myotonias

Start date: February 2006
Phase: N/A
Study type: Observational

Nondystrophic myotonias (NDM) are muscle disorders caused by genetic abnormalities in certain muscle cell membrane proteins. Individuals with NDM experience limited muscle relaxation, which causes pain, weakness, and impaired physical activity. The purpose of this study is to better characterize the clinical features and symptoms of NDM.

NCT ID: NCT00004802 Completed - Clinical trials for Paramyotonia Congenita

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders

Start date: June 1992
Phase: Phase 3
Study type: Interventional

OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic paralysis.